# Maze Therapeutics, Inc.: financial statements, quarterly

MAZE · Nasdaq · CIK 1842295 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/maze.md) · [Financials](/companies/maze/financials.md) · [Filings](/companies/maze/filings.md) · [Insiders](/companies/maze/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/maze/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [165](/filings/0000950170-25-107306.md) | [2.5](/filings/0001193125-25-269689.md) | [0.0 d](/filings/0001193125-26-122778.md) | not reported | [0.0](/filings/0000950170-25-107306.md) | not reported | not reported | [20.0](/filings/0001193125-26-219430.md) | [0.0 d](/filings/0001193125-26-344903.md) |
| Research and development | $m | [21.9](/filings/0000950170-25-071375.md) | [19.5](/filings/0000950170-25-107306.md) | [19.9](/filings/0001193125-25-269689.md) | [22.2 d](/filings/0001193125-26-122778.md) | [27.6](/filings/0001193125-26-219430.md) | [28.1](/filings/0001193125-26-344903.md) | [25.2](/filings/0001193125-25-269689.md) | [27.6 d](/filings/0001193125-26-122778.md) | [34.1](/filings/0001193125-26-219430.md) | [34.9](/filings/0001193125-26-344903.md) |
| Operating income | $m | [(28.0)](/filings/0000950170-25-071375.md) | [140](/filings/0000950170-25-107306.md) | [(24.2)](/filings/0001193125-25-269689.md) | [(29.7) d](/filings/0001193125-26-122778.md) | [(35.4)](/filings/0001193125-26-219430.md) | [(36.5)](/filings/0001193125-26-344903.md) | [(33.0)](/filings/0001193125-25-269689.md) | [(38.1) d](/filings/0001193125-26-122778.md) | [(26.6)](/filings/0001193125-26-219430.md) | [(48.0)](/filings/0001193125-26-344903.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.9](/filings/0001193125-26-219430.md) | [0.9](/filings/0001193125-26-344903.md) |
| Income tax | $m | not reported | [1.7](/filings/0000950170-25-107306.md) | [(0.3)](/filings/0001193125-25-269689.md) | [(0.3) d](/filings/0001193125-26-122778.md) | not reported | [0.0](/filings/0000950170-25-107306.md) | [0.0](/filings/0001193125-25-269689.md) | [0.0 d](/filings/0001193125-26-122778.md) | not reported | not reported |
| Net income | $m | [(32.5)](/filings/0001193125-25-269689.md) | [139](/filings/0001193125-25-269689.md) | [(24.8)](/filings/0001193125-25-269689.md) | [(29.6) d](/filings/0001193125-26-122778.md) | [(32.8)](/filings/0001193125-26-344903.md) | [(33.7)](/filings/0001193125-26-344903.md) | [(30.1)](/filings/0001193125-25-269689.md) | [(34.6) d](/filings/0001193125-26-122778.md) | [(24.2)](/filings/0001193125-26-344903.md) | [(44.7)](/filings/0001193125-26-344903.md) |
| Diluted EPS | $ per share | [(13.91)](/filings/0000950170-25-071375.md) | [3.22](/filings/0000950170-25-107306.md) | [(10.25)](/filings/0001193125-25-269689.md) | not reported | [(1.15)](/filings/0001193125-26-219430.md) | [(0.77)](/filings/0001193125-26-344903.md) | [(0.66)](/filings/0001193125-25-269689.md) | not reported | [(0.45)](/filings/0001193125-26-219430.md) | [(0.76)](/filings/0001193125-26-344903.md) |
| Basic EPS | $ per share | [(13.91)](/filings/0000950170-25-071375.md) | [5.92](/filings/0000950170-25-107306.md) | [(10.25)](/filings/0001193125-25-269689.md) | not reported | [(1.15)](/filings/0001193125-26-219430.md) | [(0.77)](/filings/0001193125-26-344903.md) | [(0.66)](/filings/0001193125-25-269689.md) | not reported | [(0.45)](/filings/0001193125-26-219430.md) | [(0.76)](/filings/0001193125-26-344903.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [30.0](/filings/0000950170-25-071375.md) | [175](/filings/0000950170-25-107306.md) | [150](/filings/0001193125-25-269689.md) | [197](/filings/0001193125-26-122778.md) | [294](/filings/0001193125-26-219430.md) | [265](/filings/0001193125-26-344903.md) | [317](/filings/0001193125-25-269689.md) | [189](/filings/0001193125-26-344903.md) | [199](/filings/0001193125-26-219430.md) | [203](/filings/0001193125-26-344903.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | [202](/filings/0001193125-26-122778.md) | [300](/filings/0000950170-25-071375.md) | [271](/filings/0000950170-25-107306.md) | [391](/filings/0001193125-25-269689.md) | [350](/filings/0001193125-26-344903.md) | [380](/filings/0001193125-26-219430.md) | [420](/filings/0001193125-26-344903.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | [241](/filings/0001193125-26-122778.md) | [333](/filings/0000950170-25-071375.md) | [304](/filings/0000950170-25-107306.md) | [422](/filings/0001193125-25-269689.md) | [397](/filings/0001193125-26-344903.md) | [420](/filings/0001193125-26-219430.md) | [532](/filings/0001193125-26-344903.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | [20.7](/filings/0001193125-26-122778.md) | [18.6](/filings/0000950170-25-071375.md) | [19.9](/filings/0000950170-25-107306.md) | [22.1](/filings/0001193125-25-269689.md) | [22.6](/filings/0001193125-26-344903.md) | [21.2](/filings/0001193125-26-219430.md) | [23.0](/filings/0001193125-26-344903.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | [43.6](/filings/0001193125-26-122778.md) | [40.8](/filings/0000950170-25-071375.md) | [41.3](/filings/0000950170-25-107306.md) | [42.6](/filings/0001193125-25-269689.md) | [42.2](/filings/0001193125-26-344903.md) | [78.0](/filings/0001193125-26-219430.md) | [78.5](/filings/0001193125-26-344903.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [38.8](/filings/0001193125-26-219430.md) | [39.0](/filings/0001193125-26-344903.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-219430.md) | [0.0](/filings/0001193125-26-344903.md) |
| Shareholders' equity | $m | [(374)](/filings/0001193125-26-122778.md) | [(404)](/filings/0001193125-25-269689.md) | [(262)](/filings/0001193125-25-269689.md) | [(285)](/filings/0001193125-25-269689.md) | [(311)](/filings/0001193125-26-122778.md) | [292](/filings/0000950170-25-071375.md) | [262](/filings/0000950170-25-107306.md) | [379](/filings/0001193125-25-269689.md) | [355](/filings/0001193125-26-344903.md) | [342](/filings/0001193125-26-219430.md) | [453](/filings/0001193125-26-344903.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest, us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(23.4)](/filings/0000950170-25-071375.md) | [145 d](/filings/0000950170-25-107306.md) | [(23.2) d](/filings/0001193125-25-269689.md) | [(22.5) d](/filings/0001193125-26-122778.md) | [(29.5)](/filings/0001193125-26-219430.md) | [(30.1) d](/filings/0001193125-26-344903.md) | [(24.6) d](/filings/0001193125-25-269689.md) | [(27.7) d](/filings/0001193125-26-122778.md) | [(39.1)](/filings/0001193125-26-219430.md) | [(15.1) d](/filings/0001193125-26-344903.md) |
| Capital expenditure | $m | [0.3](/filings/0000950170-25-071375.md) | [0.2 d](/filings/0000950170-25-107306.md) | [0.1 d](/filings/0001193125-25-269689.md) | [0.6 d](/filings/0001193125-26-122778.md) | [0.3](/filings/0001193125-26-219430.md) | [0.4 d](/filings/0001193125-26-344903.md) | [0.1 d](/filings/0001193125-25-269689.md) | [0.0 d](/filings/0001193125-26-122778.md) | [0.1](/filings/0001193125-26-219430.md) | [0.1 d](/filings/0001193125-26-344903.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.3](/filings/0000950170-25-071375.md) | [4.3](/filings/0000950170-25-107306.md) | [2.4](/filings/0001193125-25-269689.md) | [28.6](/filings/0001193125-26-219430.md) | [43.8](/filings/0001193125-26-344903.md) | [45.8](/filings/0001193125-25-269689.md) | [53.9](/filings/0001193125-26-219430.md) | [59.0](/filings/0001193125-26-344903.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 55,549,168 at 2026-08-05, from the cover of the [10-Q filed 2026-08-11](/filings/0001193125-26-344903.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.